SAN JOSE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (NASDAQ:VNUS), a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, announced today that it has asserted patent infringement claims in the United States District Court, Northern District of California, against AngioDynamics, Inc. (NASDAQ:ANGO) and Vascular Solutions, Inc. (NASDAQ:VASC), respectively.
AngioDynamics and Vascular Solutions market endovenous laser ablation products for use in procedures which VNUS believes infringe several of its patents. VNUS is seeking an injunction prohibiting AngioDynamics and Vascular Solutions from selling these products, in addition to monetary damages. These claims were added to the lawsuit that VNUS brought against Diomed Holdings, Inc. (AMEX:DIO) in July 2005, and are based on the same patents that are asserted against Diomed.
About VNUS Medical Technologies, Inc.
VNUS is a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition caused by incompetent vein valves in the leg. VNUS sells the Closure(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. For more information, please visit the corporate website at http://www.vnus.com/.
Forward-Looking Statements VNUS has made forward-looking statements in this press release within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," or variations of such words, are intended to identify such forward-looking statements in this press release. These statements are based on information available to VNUS as of the date of this press release and represent VNUS' judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors, including, among other things, the uncertain outcome of patent litigation. Therefore, the reader is cautioned not to rely on these forward-looking statements. VNUS expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. DATASOURCE: VNUS Medical Technologies, Inc.
CONTACT: Brian Farley, President and Chief Executive Officer of VNUS Medical Technologies, Inc., +1-408-473-1199, or fax, +1-408-944-0292, or Web site: http://www.vnus.com/
|